Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
Active for Non-Small Cell Lung Cancer (RAIN Trial)
Phase 2
Waitlist Available
Led By Stephen V Liu, MD
Research Sponsored by Rain Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 10 months.
Awards & highlights
No Placebo-Only Group
Summary
Open-label, Phase 2, single treatment arm, 3 cohorts
Eligible Conditions
- Non-Small Cell Lung Cancer
- Epidermal Growth Factor Receptor Mutations
- Breast Cancer
- ERBB Fusion
- Neuroblastoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 10 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 10 months.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
ORR
Side effects data
From 2015 Phase 4 trial • 88 Patients • NCT021257345%
Cough
2%
Nasal congestion
2%
Headache
2%
Nasopharyngitis
1%
Pain in extremity
1%
Palpitations
1%
Productive cough
1%
Fluid retention
1%
Muscle spasms
1%
Hypertension
1%
Dyspnoea
1%
Pruritus
1%
Renal pain
1%
Hypertriglyceridaemia
1%
Arthralgia
1%
Rhinorrhoea
1%
Nausea
1%
Peripheral swelling
1%
Bronchitis
1%
Herpes zoster
1%
Rhinitis
1%
Sinusitis
1%
Laceration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tiotropium
QVA149
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
tarloxotinib bromide
Find a Location
Who is running the clinical trial?
Rain Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
241 Total Patients Enrolled
Rain Oncology IncLead Sponsor
8 Previous Clinical Trials
278 Total Patients Enrolled
Stephen V Liu, MDPrincipal InvestigatorGeorgetown University
Share this study with friends
Copy Link
Messenger